Antiretroviral therapy coverage in Mauritania
Mauritania: Antiretroviral therapy coverage was 76.0% in 2024. ◆ Volatile
Antiretroviral therapy coverage in Mauritania, 2000–2024
Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of people living with HIV.
Analysis
In 2024, antiretroviral therapy coverage in Mauritania stood at 76.0%. That is the highest value across all 25 years on record.
The figure is up 8.6% on the previous year and up 171.4% over ten years.
Over the whole period, antiretroviral therapy coverage in Mauritania peaked at 76.0% in 2024 and was at its lowest, 0.0%, in 2000.
That places Mauritania 61st out of 143 countries with data for 2024, putting it in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Antiretroviral therapy coverage in Mauritania, year by year
| Year | % of people living with HIV | Change |
|---|---|---|
| 2000 | 0.0% | — |
| 2001 | 0.0% | — |
| 2002 | 0.0% | — |
| 2003 | 0.0% | — |
| 2004 | 1.0% | — |
| 2005 | 2.0% | +100.0% |
| 2006 | 5.0% | +150.0% |
| 2007 | 8.0% | +60.0% |
| 2008 | 11.0% | +37.5% |
| 2009 | 14.0% | +27.3% |
| 2010 | 17.0% | +21.4% |
| 2011 | 19.0% | +11.8% |
| 2012 | 21.0% | +10.5% |
| 2013 | 26.0% | +23.8% |
| 2014 | 28.0% | +7.7% |
| 2015 | 33.0% | +17.9% |
| 2016 | 36.0% | +9.1% |
| 2017 | 44.0% | +22.2% |
| 2018 | 45.0% | +2.3% |
| 2019 | 51.0% | +13.3% |
| 2020 | 54.0% | +5.9% |
| 2021 | 59.0% | +9.3% |
| 2022 | 62.0% | +5.1% |
| 2023 | 70.0% | +12.9% |
| 2024 | 76.0% | +8.6% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 4.1% | 0.0% | 14.0% | 10 |
| 2010s | 32.0% | 17.0% | 51.0% | 10 |
| 2020s | 64.2% | 54.0% | 76.0% | 5 |
Countries ranked near Mauritania
- 59 Nepal 77.0% compare
- 59 United Arab Emirates 77.0% compare
- 61 Canada 76.0% compare
- 61 El Salvador 76.0% compare
- 61 Morocco 76.0% compare
More health data for Mauritania
- Un projection of annual infant deaths, annual growth rate -0.8878 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 1.19 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 653 deaths per 1,000 people (2090)
- Number of infants who die before age 1 1,563 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate 1.77 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.077 units per person (2025)
- Population ages 00-04, male, annual growth rate 1.77 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is antiretroviral therapy coverage in Mauritania?
- Antiretroviral therapy coverage in Mauritania was 76.0% in 2024, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
- What is the highest antiretroviral therapy coverage recorded in Mauritania?
- The highest recorded value was 76.0% in 2024.
- What is the lowest antiretroviral therapy coverage recorded in Mauritania?
- The lowest recorded value was 0.0% in 2000.
- How does Mauritania rank for antiretroviral therapy coverage?
- Mauritania ranks 61st out of 143 countries with data for 2024.
- Is antiretroviral therapy coverage rising or falling in Mauritania?
- Over the last ten years it is up 171.4%. The long-run trend across the full record is volatile.
- Where does this Mauritania data come from?
- The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage (% of people living with HIV). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Antiretroviral therapy coverage indicates the percentage of all people living with HIV who are receiving antiretroviral therapy.